Nervonik's Revolutionary Study Sets New Benchmark for Nerve Sensing Technology in Chronic Pain Treatment

Groundbreaking Advances in Nerve Sensing Technology by Nervonik

Nervonik, a pioneer in clinical-stage medical device innovations, has announced significant progress in the field of chronic pain management. The company has completed a first-of-its-kind feasibility study that successfully recorded nerve-related biosignals through peripheral nerve stimulation (PNS) in human subjects. This study represents a key advancement in understanding and treating chronic pain, as it highlights the versatility of nerve sensing technology.

The Study Details

Conducted in collaboration with expert physicians at the Hospital Punta Pacifica located in Panama City, Panama, the study involved eight chronic pain patients. Each participant had neurostimulation leads implanted, aiming to demonstrate the capability of capturing essential biosignals from 16 peripheral nerves across various anatomical regions. The focus of this groundbreaking study was to record evoked compound action potentials (ECAPs)—the electrical signals produced when nerves respond to stimulation along with muscle potentials. These signals are crucial for refining therapies, indicating treatment effectiveness.

Dr. Timothy Deer, President and CEO of The Spine and Nerve Centers of the Virginias, emphasized the study’s unprecedented outcomes, stating, "This marks the first-ever instance where such signals from peripheral nerves in chronic pain patients were successfully recorded. It's a thrilling leap forward in nerve sensing technology."

Importance of Accurate Biosignal Recording

The successful documentation of precise nerve signals is a cornerstone for advancing artificial intelligence (AI) applications in medical treatments. Data accumulation from these recordings serves a vital purpose: training machine learning algorithms to individually tailor therapies to patients' evolving conditions. Aydin Babakhani, CEO and founder of Nervonik, expressed excitement, saying, "Our ability to capture these electrical signals integrates new methodologies, showcasing exceptional collaboration among scientists, engineers, and healthcare professionals."

Nervonik's innovative approach merges stimulation, sensing, and artificial intelligence, aiming for therapies that adjust based on real-time feedback from patient responses. This represents an essential step towards developing closed-loop systems capable of providing more precise, personalized treatments for chronic pain management.

Presentation and Future Implications

The findings of this study garnered attention, earning recognition as a Top Abstract by the American Society of Pain and Neuroscience (ASPN). Dr. Deer is set to present the comprehensive data during the upcoming ASPN 2026 Annual Conference in Miami Beach, Florida, slated for July 2026.

Experts in the field anticipate that advancements in biosignal recording and closed-loop stimulation could redefine the therapeutic landscape for patients grappling with chronic pain. As technologies like this evolve, they will likely pave the way for more adaptive and responsive medical interventions, improving not only efficacy but also the overall comfort of patients.

About Nervonik

Headquartered in Los Angeles, California, Nervonik, Inc. is at the forefront of innovation in neuromodulation technologies. The firm is dedicated to developing therapies that meet the unique needs of those with chronic pain and other neurological conditions. With a strong commitment to integrating intelligent solutions in medical devices, Nervonik is poised to revolutionize patient treatment paradigms.

In conclusion, Nervonik’s recent study marks a significant achievement in nerve sensing technology. It holds great promise for the future of personalized medicine, offering new hope for patients seeking relief from chronic pain and enhancing the understanding of neural responses attached to therapeutic interventions.